AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

CompletedOBSERVATIONAL
Enrollment

280

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

GAG score

blood and urine samples to determine GAG scores

Trial Locations (29)

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Emory University School of Medicine, Atlanta

77030

MD Anderson Cancer Center, Houston

Unknown

UZ Leuven, Leuven

Prostate Cancer Centre, Calgary

Aarhus University Hospital, Aarhus

Odense University Hospital, Odense

Zealand University Hospital, Roskilde

Helsinki University Central Hospital, Helsinki

Hôpital Henri Mondor, Créteil

AOU San Orsola Malpighi, Bologna

Careggi University Hospital, Florence

San Raffaele Hospital, Milan

AOU San Luigi Gonzaga, Orbassano

Istituto Nazionale Tumori Regina Elena, Roma

AOU Integrata Verona, Verona

Hospital da Luz Coimbra, Coimbra

Hospital Universitario Cabueñes, Gijón

University Hospital of Valencia, Valencia

Sahlgrenska University Hospital, Gothenburg

Norrlands University Hospital, Umeå

Addenbrooke's Hospital, Cambridge

Western General Hospital, Edinburgh

Frimley Park Hospital, Frimley

Guys & St Thomas Hospital, London

Royal Free Hospital, London

Norfolk & Norwich University Hospital, Norwich

Royal Berkshire Hospital, Reading

Salford Royal NHS Foundation Trust, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Elypta

INDUSTRY

NCT04006405 - AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC | Biotech Hunter | Biotech Hunter